With all of the hoopla on Capitol Hill over Valeant Pharmaceuticals International Inc.'s aggressive pricing practices involving drugs like Isuprel (isoprenaline) and Nitropress (sodium nitroprusside) – whose prices were hiked considerably after the company acquired the medicines from Marathon Pharmaceuticals in February – it was inevitable it wouldn't take long until federal prosecutors got involved.
And they did.